Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients
Authors:
- P RyvlinPRP Ryvlin
- G De LamérieGLG De Lamérie
- M C GrégoireMGM C Grégoire
- F MauguièreFMF Mauguière
Open Access
- 1 November 1998
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 121 (11) , 2067-2081
Abstract
We assessed the clinical utility of [11C]flumazenil-PET (FMZ-PET) prospectively in 100 epileptic patients undergoing a pre-surgical evaluation, and defined the specific contribution of this neuro-imaging technique with respect to those of MRI and [18F]fluorodeoxyglucose-PET (FDG-PET). All patients benefited from a long term video-EEG monitoring, whereas an intracranial EEG investigation was performed in 40 cases. Most of our patients (73%) demonstrated a FMZ-PET abnormality; this hit rate was significantly higher in temporal lobe epilepsy (94%) than in other types of epilepsy (50%) (P < 0.001). Most FMZ-PET findings coexisted with a MRI abnormality (81%), including hippocampal atrophy (35%) and focal hypometabolism on FDG-PET (89%). The area of decreased FMZ binding was often smaller than that of glucose hypometabolism (48%) or larger than that of the MRI abnormality (28%). FMZ-PET did not prove superior to FDG-PET in assessing the extent of the ictal onset zone, as defined by intracranial EEG recordings. However, it provided useful data which were complementary to those of MRI and FDG-PET in three situations: (i) in temporal lobe epilepsy associated with MRI signs of hippocampal sclerosis, FMZ-PET abnormalities delineated the site of seizure onset precisely, whenever they were coextensive with FDG-PET abnormalities; (ii) in bi-temporal epilepsy, FMZ-PET helped to confirm the bilateral origin of seizures by showing a specific pattern of decreased FMZ binding in both temporal lobes in 33% of cases; (iii) in patients with a unilateral cryptogenic frontal lobe epilepsy, FMZ-PET provided further evidence of the side and site of seizure onset in 55% of cases. Thus, FMZ-PET deserves to be included in the pre-surgical evaluation of these specific categories of epileptic patients, representing approximately half of the population considered for epilepsy surgery.Keywords
This publication has 22 references indexed in Scilit:
- Mesial atrophy and outcome after amygdalohippocampectomy or temporal lobe removalAnnals of Neurology, 1996
- Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: An 11C‐flumazenil PET studyAnnals of Neurology, 1996
- MRI-Guided Flumazenil- and FDG-PET in Temporal Lobe EpilepsyNeuroImage, 1996
- Interictal cerebral metabolism and epilepsy in cavernous angiomasBrain, 1995
- Functional neuroimaging strategy in temporal lobe epilepsy: A comparative study of 18FDG‐PET and 99mTc‐HMPAO–SPECTAnnals of Neurology, 1992
- Autoradiographic analysis of benzodiazepine binding in entorhinal-kindled rat brainsBrain Research, 1989
- IN-VIVO DEMONSTRATION OF REDUCED BENZODIAZEPINE RECEPTOR BINDING IN HUMAN EPILEPTIC FOCIThe Lancet, 1988
- Improved multipolar foramen ovale electrode monitoringJournal of Epilepsy, 1988
- Benzodiazepine receptor increases after repeated seizures: evidence for localization to dentate granule cells.Proceedings of the National Academy of Sciences, 1982
- Repeated seizures induce long-term increase in hippocampal benzodiazepine receptors.Proceedings of the National Academy of Sciences, 1980